Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant hepatitis b vaccine (hansenula polymorpha)
- Development stage
- Unknown
- Lead developer
- Grand Theravac Life Science Nanjing
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant hepatitis b vaccine (hansenula polymorpha) is a prophylactic vaccine intended for the prevention of hepatitis B infection. It is manufactured using recombinant DNA technology in the yeast **Hansenula polymorpha**, which expresses the hepatitis B surface antigen (**HBsAg**). The antigen is then isolated, purified, and formulated with suitable adjuvants such as aluminum salts and, in some formulations, CpG oligonucleotides. The vaccine works by stimulating an immune response that produces protective anti-HBs antibodies, conferring immunity against hepatitis B virus. This specific formulation utilizes the Hansenula polymorpha yeast strain as the expression system, which is an alternative to the more common Saccharomyces cerevisiae system. It is commercially manufactured and approved in several countries, with a favorable safety and immunogenicity profile relative to other recombinant hepatitis B vaccines[1][3][5].
- Brand names
- Biltavax
- Other names
- recombinant hepatitis b vaccine (hansenula polymorpha)recombinant hepatitis B vaccine (Hansenula polymorpha,CpG and Aluminum Adjuvant)recombinant hepatitis B vaccinehepatitis B vaccine (Hansenula polymorpha yeast-derived)HBV vaccine (Hansenula polymorpha)
02
Targets
HBsAg (Hepatitis B surface antigen)Hepatitis B surface antigen-specific T-cell receptor
Beyond the preview
Go deeper on recombinant hepatitis b vaccine (hansenula polymorpha).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant hepatitis b vaccine (hansenula polymorpha).